in the united states it is approved for the treatment of moderate to severe plaque psoriasis tildrakizumab was designed to block interleukin 23 a cytokine that plays an important role in managing the immune system and autoimmune disease originally developed by schering plough this drug became part of merck s clinical program following that company s acquisition of schering plough in september 2014 sun pharmaceutical acquired worldwide rights to tildrakizumab for use in all human indications from merck in exchange for an upfront payment of 80 million upon product approval sun pharmaceutical will be responsible for regulatory activities including subsequent submissions pharmacovigilance post approval studies manufacturing and commercialization of the approved product as of march 2014 the drug was in phase iii clinical trials for plaque psoriasis the two trials enrolled nearly 2000 patients in 2016 tildrakizumab became the first il 23p19 inhibitor to demonstrate positive results in phase 3 clinical trials for the treatment of moderate to severe plaque psoriasis further validating the importance of the role of il 23 in psoriasis sun pharma signed a licensing pact with spain s almirall for marketing tildrakizumab in europe in march 2018 it was approved by the food and drug administration